It has been demonstrated that the dual EGFR/HER-2 kinase inhibitor lapatinib sensitizes BRAF-mutant thyroid cancers to BRAF kinase inhibitors by blocking the rebound of MAPK/ERK pathway and the activation of the PI3K/AKT pathway [16]. This evidence concerns the gene EGFR and thyroid gland carcinoma.